Payment overview · 2025
General Payments
$5,538.87
61 reported records · 18 companies
Healthcare provider profile · identity verified
Patrick Huynh, DO
Allopathic & Osteopathic Physicians|Internal Medicine · NORCROSS, GA · NPI 1245761303
Verified facts
What the public records show
CMS Open Payments records show Patrick Huynh, DO received $5,538.87 in general payments during 2025 across 61 reported records.
AstraZeneca Pharmaceuticals LP accounted for 82.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,587.30 | 82.8% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $211.76 | 3.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.09 | 3.5% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $91.09 | 1.6% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $63.53 | 1.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.03 | 0.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.85 | 0.8% | 2 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $44.00 | 0.8% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.31 | 0.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.81 | 0.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.89 | 0.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.53 | 0.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.55 | 0.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.40 | 0.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.18 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.90 | 0.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.70 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,250.00 | 5 |
| Food and Beverage | $1,288.87 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $4,421.92 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.68 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $175.36 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $111.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.65 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $63.53 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.63 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.71 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $40.31 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $10.41 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 65 |
| Losartan Potassium | Losartan Potassium | 152 | 54 |
| Omeprazole | Omeprazole | 129 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 126 | 44 |
| Farxiga | Dapagliflozin Propanediol | 116 | 23 |
| Alendronate Sodium | Alendronate Sodium | 102 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 91 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 17 |
| Metformin Hcl | Metformin Hcl | 87 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 85 | 23 |
| Prednisone | Prednisone | 82 | 63 |
| Gabapentin | Gabapentin | 81 | 38 |
| Montelukast Sodium | Montelukast Sodium | 81 | 36 |
| Jardiance | Empagliflozin | 76 | 18 |
| Metformin Hcl Er | Metformin Hcl | 76 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 29 |
| Lisinopril | Lisinopril | 68 | 26 |
| Celecoxib | Celecoxib | 66 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 25 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 62 | 19 |
| Finasteride | Finasteride | 60 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Mirtazapine | Mirtazapine | 54 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 20 |
| Meloxicam | Meloxicam | 52 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 22 |
| Potassium Chloride | Potassium Chloride | 43 | 13 |
| Azithromycin | Azithromycin | 42 | 36 |
| Prolia | Denosumab | 39 | 23 |
| Glimepiride | Glimepiride | 37 | 18 |
| Trazodone Hcl | Trazodone Hcl | 37 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 25 |
| Fluocinonide | Fluocinonide | 35 | 13 |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 19 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Torsemide | Torsemide | 29 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Famotidine | Famotidine | 28 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | 14 |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Naproxen | Naproxen | 19 | 12 |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Tradjenta | Linagliptin | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Clonidine Hcl | Clonidine Hcl | 18 | 14 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Ammonium Lactate | Ammonium Lactate | 17 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Colchicine | Colchicine | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,538.87 · 61 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, ETERNA, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, GARDASIL 9, INSPIRE, INTERSTIM, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, PYRUKYND, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error